The UK’s Medicines and Healthcare products Regulatory Agency has released its 2025-2026 Public Sector Equality Duty report, demonstrating a systematic approach to advancing health equity within pharmaceutical regulation. The report showcases how regulatory agencies can operationalize equity principles across three critical domains: medicine approval processes, public engagement initiatives, and workforce composition.
The MHRA has integrated equality impact assessments into standard regulatory review procedures, ensuring that licensing and safety monitoring decisions account for differential health outcomes across protected characteristic groups including age, disability, race, and socioeconomic status. Simultaneously, the agency has redesigned public consultation processes to actively incorporate voices from historically underrepresented communities.
These reforms signal a meaningful shift in regulatory governance, positioning health equity not as a supplementary consideration but as foundational to pharmaceutical oversight. The report indicates that systematic policy reform, combined with inclusive engagement practices, can meaningfully advance health justice at the regulatory level.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: MHRA Reports Progress on Health Equity Through Regulatory Reform →
